Table 3.

MRS metabolite concentrations for all subjects, Mean (SD).

	Acute MRS (DOL 5)			Convalescent MRS
CNS metabolite (mM)	Pre-NVD Trough (n = 24)	Post-NVD Peak (n = 24)	Post-NVD Post-Peak (n = 10)	DOL 11–40 (n = 18)
GSH	1.61 ± 0.28 *	1.93 ± 0.31 *	1.77 ± 0.32	2.05 ± 0.37
Total Creatine	6.49 ± 0.7 *	7.06 ± 0.53 *,†	6.98 ± 0.81 †	6.93 ± 0.55
Total Choline	2.43 ± 0.3 ‡	2.67 ± 0.3 *,‡	2.46 ± 0.30 *	2.63 ± 0.33
NAA	4.62 ± 0.5	4.84 ± 0.46	4.55 ± 0.71	5.11 ± 0.81
Glutamate + glutamine	6.59 ± 0.94	6.37 ± 0.57	7.04 ± 0.74	7.35 ± 1.08
MyoInositol	7.12 ± 0.95 †	7.65 ± 0.91 †	7.13 ± 0.70	7.83 ± 0.97

Comparing MRS metabolites over 3 scans during the acute HIE phase, before and after NVD infusion on DOL5, intent to treat analysis: overall ANOVAs are significant for GSH (p = 0.012), tCr (p = 0.005), tCho (p = 0.001); mIns (p = 0.009). Specific groups that were significantly different by pairwise comparisons are noted by * p < 0.05, ^† p < 0.005, ^‡ p< 0.0005.